14 results about "Cancer cell lines" patented technology

This invention relates to a novel compound derived from nutmeg and an anticancer composition comprising the same. The present invention isolates several novel compounds derived from nutmeg extract and confirms that most of these novel compounds exhibit cytotoxic activity against various cancer cell lines. Five compounds (3, 4, 6, 9, and 11) were identified as having high cytotoxic activity against gastric and colorectal cancers. In particular, the compound represented by chemical formula 3 was confirmed to not only effectively induce apoptosis by regulating the cell cycle of cancer cells but also effectively inhibit tumor growth in xenograft mouse models, thus making it an effective anticancer composition.

The application discloses a powder back fern acid derivative containing a 1,2,3-triazole group and a preparation method and application thereof, and belongs to the field of pharmaceutical chemical industry. The powder back fern acid is used as a substrate, first reacts with propargylamine under the action of a condensing agent to obtain an intermediate N-propargyl powder back fern amide, then undergoes a click reaction with an azide compound to synthesize a series of powder back fern acid derivatives containing a 1,2,3-triazole. The powder back fern acid derivatives obtained are tested for cytotoxicity on five common cancer cell lines. The results show that most of the compounds exhibit obvious anti-proliferation activity on the five cancer cell lines, and meanwhile, some of the compounds can reach more than half of the inhibition rate on the five cancer cell lines at a concentration of 10 muM. The synthesis process is simple and fast, and the synthesis efficiency is high. The application is another effective way for synthesizing new compounds by modifying the structure of the powder back fern acid after amination. The powder back fern acid derivatives prepared by synthesis are expected to be applied in the field of antitumor drugs.

The present disclosure relates to an anti-B7-H3 antibody or an antigen-binding fragment thereof, which binds to a specific epitope located within the amino acid sequence of a domain of B7-H3. The antibody (i) specifically binds to various types of cancer cell lines expressing B7-H3, demonstrating T cell-mediated cancer cell-killing effect, and (ii) binds to epitopes in both humans and mice, thus allowing for effective evaluation of anticancer effect in preclinical trials when developed into a therapeutic antibody.

The application provides a sesquiterpene dimer compound, a preparation method and application, and belongs to the field of medical biotechnology. The sesquiterpene dimer compound is extracted and separated from a Lemnalia soft coral to obtain a sesquiterpene dimer compound lemnalinoid L. The sesquiterpene dimer compound lemnalinoid L has an antitumor effect, has inhibitory activity on a human breast cancer cell line MDA-MB-231, can be used for developing a candidate molecule for treating the disease, and can be used as a lead compound for chemical synthesis and structural modification of other drugs. The preparation method is simple and fast, and the extracted new diterpene glycoside compound has high purity.

The application discloses a kind of based on knowledge graph's cancer cell line drug response prediction large language model construction method.The method fuses the structured information of biological knowledge graph and the semantic reasoning ability of large language model, realizes the multi-level modeling and explainable prediction of drug-cell reaction mechanism.The method comprises the following steps: first, integrate multi-source data to construct multi-modal dataset;Second, establish the drug response knowledge graph containing drug, gene and other entities;Then, fine-tune the model using LoRA technology and inject graph embedding, realize cross-modal alignment;Further, dynamic knowledge retrieval and enhancement are carried out using RAG technology;Finally, output drug sensitivity prediction and natural language explanation.The application significantly improves the prediction accuracy and explainability, and can reveal the key gene pathway, providing an efficient intelligent tool for precision cancer treatment.

This application relates to the delivery of substances to enucleated cells. Current subject matter includes methods, systems, articles, and techniques for delivering substances to enucleated cells such as red blood cells. Using rapidly deformable microfluidic systems, loading red blood cells with macromolecules of varying sizes has been demonstrated. While delivery to some mammalian cells, such as cancer cell lines and fibroblasts, using this technique has previously been shown, these designs are incompatible with RBCs, which have significantly different physical properties. Successful delivery to red blood cells can be achieved by using smaller contractile portion sizes, high speeds, and different buffer solutions. By achieving robust delivery to red blood cells in a simple and scalable manner, the current subject matter can be implemented in a variety of applications, such as delivering substances for studying red blood cell diseases and / or using red blood cells as a therapeutic platform. Related devices, systems, techniques, and articles are also described.

This invention belongs to the field of biodetection and treatment technology, specifically relating to the innovative application of a novel circRNA, circM-TMEFF1, in the diagnosis and treatment of hepatocellular carcinoma (HCC). circM-TMEFF1 forms a circular structure and is specifically low-expressed in HCC cancer cells. Specifically, this invention provides the application of circM-TMEFF1 as a biomarker in the preparation of diagnostic or prognostic kits for HCC. Compared with normal controls, the expression level of circM-TMEFF1 is significantly downregulated in HCC tissues and tumor recurrence tissues, thus serving as a biomarker for the diagnosis and prognosis of HCC. Furthermore, promoting circM-TMEFF1 expression can effectively inhibit the proliferation and growth of HCC cancer cell lines, providing a new target for improving HCC treatment and possessing significant clinical value.

The invention describes peptides with anticancer activity and exhibiting antagonistic activity against CD133 protein, which were obtained and designed by means of computer tools, evaluating physicochemical parameters of flexibility, hydrophilicity, hydrophobicity, antigenicity and total charge as described herein, in addition to the modeling of the protein, which allowed selecting 4 regions with the appropriate characteristics. After modeling the selected peptides, CD133 peptide-protein molecular docking was performed, where stable interactions were observed, even showing hydrogen bonds. Finally, the peptides of the invention showed anticancer effects against several cancer cell lines, including cancer cells resistant to conventional treatments such as triple negative breast cancer cells.

The application relates to the technical field of metal organic complexes, in particular to a chiral Au 16 Metal complex and preparation method and application thereof. By using a specific chiral 1,4-di (dithiocarbamate) -2-methyl piperazine potassium salt ligand, a specific chiral Au 16 Metal complex, 16 Au atoms in the structure of the metal complex form an Au 16 Macrocycle, 16 gold atoms form a polynuclear gold compound, and the chiral Au 16 Drug activity of the metal complex on cancer cells. In in-vitro cell experiments, the chiral Au 16 The metal complex has good in-vitro anticancer activity in different cancer cell lines. Meanwhile, due to the Au-Au bonding, a macrocycle structure is formed, and the chiral Au 16 Cytotoxicity of the metal complex on normal cells.

The invention relates to the field of three-dimensional cell culture and relates, in particular, to cellular microcompartments, without an extracellular matrix of animal origin, and / or derived from cancer cell lines, for the production of GMP-grade cells and tissues.

The present invention relates to a novel tubulin polymerization inhibitor, a preparation method therefor, and a pharmaceutical composition for treating cancer containing same as an active ingredient. A novel tubulin polymerization inhibitor compound or a pharmaceutically acceptable salt thereof according to the present invention exhibits a high inhibitory ability against various cancer cell lines, thereby being able to be effectively used as a pharmaceutical composition for preventing or treating cancer or a health functional food composition for preventing or alleviating cancer.

This invention discloses terpenoid compounds with anticancer activity and their preparation methods, belonging to the field of biotechnology. The invention employs a chemical-enzymatic method, first chemically synthesizing the natural substrate analog 7-O-FPP, and then using the sesquiterpene synthase TmS for in vitro catalysis to obtain three oxygen-containing sesquiterpene products. MTT activity assays showed that the three compounds exhibited significant anticancer activity against gastric cancer SGC7901, lung cancer NCI-H1975, cervical cancer HeLa, and esophageal squamous cell carcinoma KYSE-150 cells. Compounds 1 and 3 showed anticancer activity against various cancer cell lines. 50 The concentration of compounds below 1 μg / mL showed significantly superior activity compared to the clinical drug β-elemene; compound 2 exhibited higher activity against lung cancer cells and low toxicity to normal MRC-5 cells. This invention provides an efficient method for preparing novel terpenoid compounds, and the resulting compounds offer high-quality lead molecules for the development of new anticancer drugs, demonstrating promising application prospects.

The present invention pertains to a combination of specific benzene sulfonamide thiazole compounds with an anticancer treatment for use in the treatment of cancer in a patient who has been identified as overexpressing GRP78. Using a colorectal cancer mice model (CT26 allograft model) and several cancer cell lines models in vitro, the present inventors have shown that a combined therapy using HA15, a benzene sulfonamide thiazole compound, and an anticancer treatment such as an immunotherapeutic agent, a chemotherapeutic agent or targeted therapies significantly improves the survival rate and strongly reduces tumor growth as compared to monotherapies comprising either a benzene sulfonamide thiazole compound or an anticancer agent alone.

This invention relates to the fields of tumor biology and cell engineering, specifically disclosing the construction and application of a human prostate cancer cell line. The human prostate cancer cell line is derived from primary prostate cancer tissue, expresses prostate-specific antigen and α-methylacyl-CoA racemic enzyme, and has a 46,XY karyotype. The construction method employs an innovative strategy of co-culturing fully digested cell suspensions with incompletely digested tissue blocks, significantly improving the success rate of establishing the cell line from the primary lesion. This cell line can stably proliferate in conventional culture media supplemented with testosterone and has been successfully applied to subcutaneous tumorigenesis models in immunodeficient mice and in vivo migration models in zebrafish. The primary lesion-derived prostate cancer cell line provided by this invention offers a highly relevant, stable, and reliable new experimental tool for studying the biological characteristics of primary prostate cancer, drug screening, and personalized treatment.